Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 108

Similar articles for PubMed (Select 24901667)

1.

4-amino-1-hydroxy-2-oxo-1,8-naphthyridine-containing compounds having high potency against raltegravir-resistant integrase mutants of HIV-1.

Zhao XZ, Smith SJ, Métifiot M, Marchand C, Boyer PL, Pommier Y, Hughes SH, Burke TR Jr.

J Med Chem. 2014 Jun 26;57(12):5190-202. doi: 10.1021/jm5001908. Epub 2014 Jun 16. Erratum in: J Med Chem. 2014 Aug 14;57(15):6885.

2.

Bicyclic 1-hydroxy-2-oxo-1,2-dihydropyridine-3-carboxamide-containing HIV-1 integrase inhibitors having high antiviral potency against cells harboring raltegravir-resistant integrase mutants.

Zhao XZ, Smith SJ, Métifiot M, Johnson BC, Marchand C, Pommier Y, Hughes SH, Burke TR Jr.

J Med Chem. 2014 Feb 27;57(4):1573-82. doi: 10.1021/jm401902n. Epub 2014 Feb 10.

3.

Bicyclic hydroxy-1H-pyrrolopyridine-trione containing HIV-1 integrase inhibitors.

Zhao XZ, Maddali K, Metifiot M, Smith SJ, Vu BC, Marchand C, Hughes SH, Pommier Y, Burke TR Jr.

Chem Biol Drug Des. 2012 Feb;79(2):157-65. doi: 10.1111/j.1747-0285.2011.01270.x. Epub 2011 Dec 22.

PMID:
22107736
4.

In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor.

Kobayashi M, Yoshinaga T, Seki T, Wakasa-Morimoto C, Brown KW, Ferris R, Foster SA, Hazen RJ, Miki S, Suyama-Kagitani A, Kawauchi-Miki S, Taishi T, Kawasuji T, Johns BA, Underwood MR, Garvey EP, Sato A, Fujiwara T.

Antimicrob Agents Chemother. 2011 Feb;55(2):813-21. doi: 10.1128/AAC.01209-10. Epub 2010 Nov 29.

5.

Synthesis of 5-(1-H or 1-alkyl-5-oxopyrrolidin-3-yl)-8-hydroxy-[1,6]-naphthyridine-7-carboxamide inhibitors of HIV-1 integrase.

Melamed JY, Egbertson MS, Varga S, Vacca JP, Moyer G, Gabryelski L, Felock PJ, Stillmock KA, Witmer MV, Schleif W, Hazuda DJ, Leonard Y, Jin L, Ellis JD, Young SD.

Bioorg Med Chem Lett. 2008 Oct 1;18(19):5307-10. doi: 10.1016/j.bmcl.2008.08.038. Epub 2008 Aug 14.

PMID:
18774711
6.

The naphthyridinone GSK364735 is a novel, potent human immunodeficiency virus type 1 integrase inhibitor and antiretroviral.

Garvey EP, Johns BA, Gartland MJ, Foster SA, Miller WH, Ferris RG, Hazen RJ, Underwood MR, Boros EE, Thompson JB, Weatherhead JG, Koble CS, Allen SH, Schaller LT, Sherrill RG, Yoshinaga T, Kobayashi M, Wakasa-Morimoto C, Miki S, Nakahara K, Noshi T, Sato A, Fujiwara T.

Antimicrob Agents Chemother. 2008 Mar;52(3):901-8. Epub 2007 Dec 26. Erratum in: Antimicrob Agents Chemother. 2008 May;52(5):1899.

7.

Comparative replication capacity of raltegravir-resistant strains and antiviral activity of the new-generation integrase inhibitor dolutegravir in human primary macrophages and lymphocytes.

Pollicita M, Surdo M, Di Santo F, Cortese MF, Fabeni L, Fedele V, Malet I, Marcelin AG, Calvez V, Ceccherini-Silberstein F, Perno CF, Svicher V.

J Antimicrob Chemother. 2014 Sep;69(9):2412-9. doi: 10.1093/jac/dku144. Epub 2014 May 23.

PMID:
24860155
8.

Mutations in human immunodeficiency virus type 1 integrase confer resistance to the naphthyridine L-870,810 and cross-resistance to the clinical trial drug GS-9137.

Hombrouck A, Voet A, Van Remoortel B, Desadeleer C, De Maeyer M, Debyser Z, Witvrouw M.

Antimicrob Agents Chemother. 2008 Jun;52(6):2069-78. doi: 10.1128/AAC.00911-07. Epub 2008 Mar 31.

9.

A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase.

Hazuda DJ, Anthony NJ, Gomez RP, Jolly SM, Wai JS, Zhuang L, Fisher TE, Embrey M, Guare JP Jr, Egbertson MS, Vacca JP, Huff JR, Felock PJ, Witmer MV, Stillmock KA, Danovich R, Grobler J, Miller MD, Espeseth AS, Jin L, Chen IW, Lin JH, Kassahun K, Ellis JD, Wong BK, Xu W, Pearson PG, Schleif WA, Cortese R, Emini E, Summa V, Holloway MK, Young SD.

Proc Natl Acad Sci U S A. 2004 Aug 3;101(31):11233-8. Epub 2004 Jul 26.

10.

Mechanisms of human immunodeficiency virus type 1 concerted integration related to strand transfer inhibition and drug resistance.

Zahm JA, Bera S, Pandey KK, Vora A, Stillmock K, Hazuda D, Grandgenett DP.

Antimicrob Agents Chemother. 2008 Sep;52(9):3358-68. doi: 10.1128/AAC.00271-08. Epub 2008 Jun 30.

11.

Comparison of raltegravir and elvitegravir on HIV-1 integrase catalytic reactions and on a series of drug-resistant integrase mutants.

Marinello J, Marchand C, Mott BT, Bain A, Thomas CJ, Pommier Y.

Biochemistry. 2008 Sep 9;47(36):9345-54. doi: 10.1021/bi800791q. Epub 2008 Aug 15.

13.

MK-0536 inhibits HIV-1 integrases resistant to raltegravir.

Métifiot M, Johnson B, Smith S, Zhao XZ, Marchand C, Burke T, Hughes S, Pommier Y.

Antimicrob Agents Chemother. 2011 Nov;55(11):5127-33. doi: 10.1128/AAC.05288-11. Epub 2011 Aug 29.

14.

Repositioning HIV-1 integrase inhibitors for cancer therapeutics: 1,6-naphthyridine-7-carboxamide as a promising scaffold with drug-like properties.

Zeng LF, Wang Y, Kazemi R, Xu S, Xu ZL, Sanchez TW, Yang LM, Debnath B, Odde S, Xie H, Zheng YT, Ding J, Neamati N, Long YQ.

J Med Chem. 2012 Nov 26;55(22):9492-509. doi: 10.1021/jm300667v. Epub 2012 Nov 7.

PMID:
23098137
15.

New hexahydrodiazocino-naphthyridine triones as HIV-1 integrase inhibitors: WO2008048538 A1.

Cotelle P.

Expert Opin Ther Pat. 2009 Jan;19(1):87-93. doi: 10.1517/13543770802603577.

PMID:
19441900
16.

Design and discovery of 5-hydroxy-6-oxo-1,6-dihydropyrimidine-4-carboxamide inhibitors of HIV-1 integrase.

Zhang D, Debnath B, Yu S, Sanchez TW, Christ F, Liu Y, Debyser Z, Neamati N, Zhao G.

Bioorg Med Chem. 2014 Oct 1;22(19):5446-53. doi: 10.1016/j.bmc.2014.07.036. Epub 2014 Jul 30.

PMID:
25150089
17.

6,7-Dihydroxy-1-oxoisoindoline-4-sulfonamide-containing HIV-1 integrase inhibitors.

Zhao XZ, Maddali K, Smith SJ, Métifiot M, Johnson BC, Marchand C, Hughes SH, Pommier Y, Burke TR Jr.

Bioorg Med Chem Lett. 2012 Dec 15;22(24):7309-13. doi: 10.1016/j.bmcl.2012.10.088. Epub 2012 Oct 27.

18.

Addition of E138K to R263K in HIV integrase increases resistance to dolutegravir, but fails to restore activity of the HIV integrase enzyme and viral replication capacity.

Mesplède T, Osman N, Wares M, Quashie PK, Hassounah S, Anstett K, Han Y, Singhroy DN, Wainberg MA.

J Antimicrob Chemother. 2014 Oct;69(10):2733-40. doi: 10.1093/jac/dku199. Epub 2014 Jun 10.

PMID:
24917583
19.

Discovery of potent HIV integrase inhibitors active against raltegravir resistant viruses.

Le G, Vandegraaff N, Rhodes DI, Jones ED, Coates JA, Lu L, Li X, Yu C, Feng X, Deadman JJ.

Bioorg Med Chem Lett. 2010 Sep 1;20(17):5013-8. doi: 10.1016/j.bmcl.2010.07.041. Epub 2010 Jul 16.

PMID:
20685117
20.

A series of 5-(5,6)-dihydrouracil substituted 8-hydroxy-[1,6]naphthyridine-7-carboxylic acid 4-fluorobenzylamide inhibitors of HIV-1 integrase and viral replication in cells.

Embrey MW, Wai JS, Funk TW, Homnick CF, Perlow DS, Young SD, Vacca JP, Hazuda DJ, Felock PJ, Stillmock KA, Witmer MV, Moyer G, Schleif WA, Gabryelski LJ, Jin L, Chen IW, Ellis JD, Wong BK, Lin JH, Leonard YM, Tsou NN, Zhuang L.

Bioorg Med Chem Lett. 2005 Oct 15;15(20):4550-4.

PMID:
16102965
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk